SCHEMBL14326239

SCHEMBL14326239

CC(C)=C1C=COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28197579 0.69
SCHEMBL11526877 0.66
SCHEMBL7708408 0.64
SCHEMBL6129972 0.63
SCHEMBL11822817 0.62
SCHEMBL318474 0.59
SCHEMBL7829463 0.57
SCHEMBL16504067 0.56
SCHEMBL20787073 0.56
SCHEMBL13228776 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758509-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2017-09-12 US disclosed
US-20170174664-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN, INC. 2017-06-22 US disclosed
US-9657005-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2017-05-23 US disclosed
US-20150099746-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN INC (US) 2015-04-09 US disclosed
US-8877923-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2014-11-04 US disclosed
US-8865682-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2014-10-21 US disclosed
US-20130217650-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN, INC. (US) 2013-08-22 US disclosed
US-20130123259-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONES AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN, INC. (US) 2013-05-16 US disclosed
US-8367664-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2013-02-05 US disclosed
US-8338415-B2 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors ALLERGAN, INC. (US) 2012-12-25 US disclosed
US-20070173500-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN, INC. (US) 2007-07-26 US disclosed
US-20070173501-A1 SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS ALLERGAN, INC. (US) 2007-07-26 US disclosed
CN-1214049-A Therapeutic compounds GLAXO GROUP LTD (GB) 1999-04-14 CN disclosed
CN-1007247-B PROCESS FOR THE PREPARATION OF NOVEL ALLYLIC AMINES MERRELL DOW PHARMA (US) 1990-03-21 CN disclosed
CN-85109441-A The preparation method of new allylic amines 1986-08-13 CN disclosed